A new clinical trial update for exenatide was recorded on July 17, 2026. The study, registered as NCT07497399 and titled "Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis," is a Phase 2 trial. Its current status is listed as recruiting.
The trial is evaluating GLP-1 receptor agonists, a drug class that includes exenatide, in the context of multiple sclerosis. No results have been posted for this study at this stage, and the update reflects only the trial's recruiting status and phase.
Exenatide remains an approved compound, and this trial represents an investigational use being studied separately from its approved indications. As the study is still in the recruiting phase, no outcome data, efficacy claims, or safety findings are available yet from this registration.
Readers interested in tracking this trial can find further details through the official ClinicalTrials.gov listing. For additional background on exenatide, including its approved uses and general profile, see the compound overview linked with this brief.